Synthesis and biological evaluation of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles as transforming growth factor-β type 1 receptor kinase inhibitors

被引：19

作者：

Kim, Dae-Kee ^{[1
]}

Jung, Sun Hee ^{[1
]}

Lee, Ho Soon ^{[2
]}

Dewang, Purushottam M. ^{[1
]}

机构：

[1] Ewha Womans Univ, Coll Pharm, Seoul 120750, South Korea

[2] In2Gen Co Ltd, Seoul 152050, South Korea

来源：

EUROPEAN JOURNAL OF MEDICINAL CHEMISTRY | 2009年 / 44卷 / 02期

关键词：

Transforming growth factor-beta (TGF-beta); ALK5; inhibitors; Fibrosis; Cancer; TGF-BETA; ALK5; INHIBITOR; FIBROSIS; MURINE; POTENT;

D O I：

10.1016/j.ejmech.2008.03.024

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

A series of benzenesulfonamide-substituted 4-(6-alkylpyridin-2-yl)-5-(quinoxalin-6-yl)imidazoles (15a-1) have been synthesized and evaluated for their ALK5 inhibitory activity in cell-based luciferase reporter assays. Among them, 4-[5-(6-methylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-ylmethyl]benzenesulfonamide (15b) and 4-[5-(6-ethylpyridin-2-yl)-4-(quinoxalin-6-yl)-1H-imidazol-2-ylmethyl]benzene-sulfonamide (15c) showed more than 90% inhibition at 0.5 mu M in a luciferase reporter assay using HaCaT cells transiently transfected with p3TP-luc reporter construct, but inhibited p38 alpha MAP kinase activity only 11 and 8% at a concentration of 10 mu M, respectively. (C) 2008 Elsevier Masson SAS. All rights reserved.

引用

页码：568 / 576

页数：9

共 31 条

[1]

Agrotis Alex, 2005, Current Vascular Pharmacology, V3, P55, DOI 10.2174/1570161052773951

[2] The effect of TGF-beta on keloid fibroblast proliferation and collagen synthesis [J].

Bettinger, DA ;

Yager, DR ;

Diegelmann, RF ;

Cohen, IK .

PLASTIC AND RECONSTRUCTIVE SURGERY, 1996, 98 (05) :827-833

[3] SB-505124 is a selective inhibitor of transforming growth factor-β type I receptors ALK4, ALK5, and ALK7 [J].

Byfield, SD ;

Major, C ;

Laping, NJ ;

Roberts, AB .

MOLECULAR PHARMACOLOGY, 2004, 65 (03) :744-752

[4]

CHAKRAVARTY S, 2003, Patent No. 03097615

[5] Inhibition of TGF-β signaling by an ALK5 inhibitor protects rats from dimethylnitrosamine-induced liver fibrosis [J].

de Gouville, AC ;

Boullay, V ;

Krysa, G ;

Pilot, J ;

Brusq, JM ;

Loriolle, F ;

Gauthier, JM ;

Papworth, SA ;

Laroze, A ;

Gellibert, F ;

Huet, S .

BRITISH JOURNAL OF PHARMACOLOGY, 2005, 145 (02) :166-177

[6] Role of transforming growth factor beta in human cancer [J].

Elliott, RL ;

Blobe, GC .

JOURNAL OF CLINICAL ONCOLOGY, 2005, 23 (09) :2078-2093

[7]

GASTER LM, 2003, Patent No. 20030149277

[8] Identification of 1,5-naphthyridine derivatives as a novel series of potent and selective TGF-β type I receptor inhibitors [J].

Gellibert, FO ;

Woolven, J ;

Fouchet, MH ;

Mathews, N ;

Goodland, H ;

Lovegrove, V ;

Laroze, A ;

Nguyen, VL ;

Sautet, S ;

Wang, RL ;

Janson, C ;

Smith, W ;

Krysa, G ;

Boullay, V ;

de Gouville, AC ;

Huet, S ;

Hartley, D .

JOURNAL OF MEDICINAL CHEMISTRY, 2004, 47 (18) :4494-4506

[9] Antifibrotic effect of decorin in a bleomycin hamster model of lung fibrosis [J].

Giri, SN ;

Hyde, DM ;

Braun, RK ;

Gaarde, W ;

Harper, JR ;

Pierschbacher, MD .

BIOCHEMICAL PHARMACOLOGY, 1997, 54 (11) :1205-1216

[10] Inhibition of gene markers of fibrosis with a novel inhibitor of transforming growth factor-β type I receptor kinase in puromycin-induced nephritis [J].

Grygielko, ET ;

Martin, WM ;

Tweed, C ;

Thornton, P ;

Harling, J ;

Brooks, DP ;

Laping, NJ .

JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS, 2005, 313 (03) :943-951

← 1 2 3 4 →